InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025)
InMed Pharmaceuticals (INM) reported Other financing activities of $137178.0 for Q3 2025, down 28.49% on a YoY basis from $191824.0 in Q3 2024, and down 77.85% quarter-over-quarter from $619419.0 in Q2 2025.
InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Other financing activities for 6 years, with the latest figure at $137178.0 in Q3 2025.
- For the quarter ending Q3 2025, Other financing activities fell 28.49% year-over-year to $137178.0; the trailing twelve-month figure through Mar 2026 stood at $756597.0 (up 161.12% YoY), and the FY2025 full-year result was $883978.0, up 57.25% from the prior year.
- Other financing activities for Q3 2025 stood at $137178.0, down from $619419.0 in the prior quarter.
- The five-year high for Other financing activities was $1.1 million in Q3 2021, with the low at $15103.0 in Q1 2025.
- Historically, Other financing activities has averaged $332266.5 across 5 years, with a median of $185471.0 in 2021.
- Annual changes were most pronounced in 2021 — Other financing activities soared 1624.92% — and 2023, when it plunged 95.59%.
- InMed Pharmaceuticals' Other financing activities stood at $179118.0 in 2021, then jumped by 282.23% to $684650.0 in 2022, then slumped by 96.32% to $25191.0 in 2023, then surged by 128.78% to $57632.0 in 2024, then jumped by 138.02% to $137178.0 in 2025.
- The last three Other financing activities figures came in at $137178.0 (Q3 2025), $619419.0 (Q2 2025), and $15103.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 137,178.00 |
| Sep 30, 2025 | 137,178.00 |
| Jun 30, 2025 | 619,419.00 |
| Jun 30, 2025 | 619,419.00 |
| Mar 31, 2025 | 15,103.00 |
| Mar 31, 2025 | 15,103.00 |
| Dec 31, 2024 | 57,632.00 |
| Dec 31, 2024 | 57,632.00 |
| Sep 30, 2024 | 191,824.00 |
| Sep 30, 2024 | 191,824.00 |
| Sep 30, 2023 | 25,191.00 |
| Sep 30, 2023 | 25,191.00 |
| Mar 31, 2023 | 63,871.00 |
| Mar 31, 2023 | 63,871.00 |
| Dec 31, 2022 | 684,650.00 |
| Dec 31, 2022 | 684,650.00 |
| Sep 30, 2022 | 571,261.00 |
| Sep 30, 2022 | 571,261.00 |
| Jun 30, 2022 | 490,544.00 |
| Jun 30, 2022 | 490,544.00 |